---
title: "Hebei Changshan Biochemical Pharmaceutical Co.,Ltd. (300255.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300255.SZ.md"
symbol: "300255.SZ"
name: "Hebei Changshan Biochemical Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T15:25:51.564Z"
locales:
  - [en](https://longbridge.com/en/quote/300255.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300255.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300255.SZ.md)
---

# Hebei Changshan Biochemical Pharmaceutical Co.,Ltd. (300255.SZ)

## Company Overview

Hebei Changshan Biochemical Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, marketing, and sale of drugs for cardiovascular, cerebrovascular, diabetes, and cancer in China and internationally. It offers heparin sodium, calcium, and lithium, as well as heparinoid, LMW heparins, and sodium hyaluronate; dalteparin sodium, enoxaparin sodium, nadroparin calcium, and heparin sodium injections, as well as sildenafil citrate tablet; and albenatide. The company is also involved in technology development; consulting; transfer services; investment and management of medical service projects; wholesale and retail of pharmaceuticals; and diagnosis services. It exports its products to the United States, Germany, France, Italy, Spain, South Korea, Japan, Russia, India, the Philippines, and other countries.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.hbcsbio.com](https://www.hbcsbio.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: D
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: D (0.78)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 179 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: D

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.33% |  |
| Net Profit YoY | -93.34% |  |
| P/B Ratio | 31.14 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 37748520282.71 |  |
| Revenue | 874085223.69 |  |

#### Multi Score Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -25.63% | E |
| Profit Margin | -40.78% | E |
| Gross Margin | 24.60% | C |
| Revenue YoY | -12.33% | E |
| Net Profit YoY | -93.34% | E |
| Total Assets YoY | -2.41% | D |
| Net Assets YoY | -23.93% | E |
| Cash Flow Margin | 7.62% | D |
| OCF YoY | -12.33% | E |
| Turnover | 0.19 | D |
| Gearing Ratio | 73.60% | D |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Hebei Changshan Biochemical Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.33%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.34%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "31.14",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "37748520282.71",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "874085223.69",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-25.63%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-40.78%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "24.60%",
          "rating": "C"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.33%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-93.34%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.41%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-23.93%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "7.62%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-12.33%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.19",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "73.60%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -104.38 | 212/215 | - | - | - |
| PB | 30.69 | 218/215 | 34.72 | 28.62 | 25.49 |
| PS (TTM) | 42.56 | 218/215 | 55.59 | 45.44 | 41.02 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/300255.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/300255.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/300255.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/300255.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**